Thomas B. King has served as a director of the Company since 2020. Mr. King brings a wealth of knowledge from 40+ years of experience in biopharma leadership positions ranging from large to development-stage companies. Mr. King has built, operated and sold multiple public specialty pharmaceutical businesses, including most recently serving as interim CEO for VIVUS, Inc. (Nasdaq: VVUS), from December 2017 to April 2018.
Prior to that, Mr. King was at Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), where he served as President, Chief Executive Officer and a member of the board of directors from June 2003 until it was acquired by Grupo Ferrer in June 2016. From September 2002 to April 2003, he served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately-held biopharmaceutical development-stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation (Nasdaq: NSTA), including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors until it was acquired in October 2000 by Cephalon, Inc.
Mr. King currently serves on the board of directors of Satsuma Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company and Concentric Analgesics, Inc., and Kinaset Therapeutics, both privately-held biopharmaceutical companies. Mr. King also serves as a Senior Advisor for Berkshire Biomedical, LLC, also a privately-held biopharmaceutical company.
Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.